A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab.

ABSTRACT: This phase 2 study evaluated the efficacy and safety of transitioning to zoledronate following romosozumab treatment in postmenopausal women with low bone mass. A single dose of 5 mg zoledronate generally maintained the robust BMD gains accrued with romosozumab treatment and was well tolerated.

Introduction

Follow-on therapy with an antiresorptive agent is necessary to maintain the skeletal benefits of romosozumab therapy. We evaluated the use of zoledronate following romosozumab treatment.

Methods

This phase 2, dose-finding study enrolled postmenopausal women with low bone mineral density (BMD). Subjects who received various romosozumab doses or placebo from months 0-24 were rerandomized to denosumab (60 mg SC Q6M) or placebo for 12 months, followed by open-label romosozumab

SUBMITTER: McClung MR 

PROVIDER: S-EPMC7560921 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature